Orange Book product · Generic (ANDA)
LIRAGLUTIDE
LIRAGLUTIDE
At a glance
Feb 24, 2026
Approved
Generic (ANDA)
Application
AP2
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 24, 2026
4 mo ago
Today
Pharmaceutical detail
Active ingredient
LIRAGLUTIDE
Strength
18MG/3ML (6MG/ML)
Dosage form
SOLUTION
Route
SUBCUTANEOUS
TE code
AP2
Application
ANDA 217234
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LIRAGLUTIDE
- 2014SAXENDABrand (NDA)
NDA 206321 · NOVO
- 2010VICTOZABrand (NDA)
NDA 022341 · NOVO NORDISK INC
- 2026LIRAGLUTIDEGeneric (ANDA)
ANDA 212552 · FRESENIUS KABI USA
- 2026LIRAGLUTIDEGeneric (ANDA)
ANDA 215245 · BIOCON PHARMA
- 2026LIRAGLUTIDEGeneric (ANDA)
ANDA 217063 · BIOCON PHARMA
- 2026LIRAGLUTIDEGeneric (ANDA)
ANDA 217590 · ORBICULAR
- 2025LIRAGLUTIDEGeneric (ANDA)
ANDA 214568 · TEVA PHARMS
- 2025LIRAGLUTIDEGeneric (ANDA)
ANDA 215421 · LUPIN
- 2025LIRAGLUTIDEGeneric (ANDA)
ANDA 218115 · NANJING KING FRIEND
- 2024LIRAGLUTIDEGeneric (ANDA)
ANDA 215503 · HIKMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
